Carbamoyl phosphate synthetase I deficiency

Carbamoyl phosphate synthetase I deficiency (CPS1D) is an ultra-rare urea cycle disorder caused by biallelic pathogenic variants in the CPS1 gene. It presents with autosomal recessive inheritance. Total or partial loss of the enzyme blocks the incorporation of ammonia into the urea cycle, causes hyperammonemia, and can lead to severe metabolic encephalopathy.

The CPS1 gene encodes carbamoyl phosphate synthetase I, an enzyme of the mitochondrial matrix primarily expressed in the liver. It catalyzes the first committed and rate-limiting step of the urea cycle: the formation of carbamoyl phosphate from ammonia and bicarbonate, consuming ATP and with N-acetylglutamate as an essential activator. This product allows the formation of citrulline and the continuation of the conversion of excess nitrogen into urea.

Pathogenic variants in CPS1 can alter the production, stability, mitochondrial localization, or catalytic activity of the protein. Almost null activity typically causes the neonatal form, whereas some residual function can lead to late-onset presentations triggered by infections, fasting, surgery, or other catabolic situations. The incidence is estimated to be around 1 in 1,300,000 individuals, although underdiagnosis exists. Most variants are familial or private; c.3037_3039del (p.Val1013del) is a recurrent exception associated with a founder effect in the Turkish population.

Symptoms

The severe form usually appears during the first days of life, after starting feeding, with refusal of feeds, vomiting, irritability, somnolence, altered temperature, hypotonia or hypertonia, and rapid breathing. Hyperammonemia can evolve to respiratory alkalosis, cerebral edema, seizures, coma, respiratory failure, and death. Survivors may present with developmental delay, intellectual disability, epilepsy, and motor disorders. Partial forms may begin in infancy or adulthood with episodes of vomiting, ataxia, lethargy, confusion, behavioral changes, or decreased consciousness. Low citrulline, elevated glutamine, low blood urea nitrogen, and normal or decreased urinary orotic acid are common.

Disease management

There is no general curative pharmacological treatment. Hyperammonemic crisis is an emergency: protein intake is temporarily interrupted, glucose and lipids are administered to reverse catabolism, nitrogen scavengers, and arginine or citrulline according to the protocol. If ammonia is very high or does not decrease rapidly, hemodialysis or continuous renal therapy may be necessary. Complete protein exclusion should not be prolonged because it promotes catabolism.

Chronic treatment combines an individualized diet with protein control and sufficient intake of energy and essential amino acids, citrulline, nitrogen scavengers when indicated, and an emergency plan for infections or fasting. Ammonia, amino acids, growth, and neurological development must be monitored. Carbamoylglutamic acid may benefit some patients with residual activity, but the response is not uniform. Liver transplantation corrects the metabolic defect and prevents new crises, although it does not reverse previous brain damage and requires immunosuppression. In 2025, an infant was treated with a personalized base editing targeting a CPS1 variant; it was an experimental intervention in a single patient, not an approved treatment, and its long-term safety and efficacy remain to be established.

Genes analyzed

CPS1 U
U Ultra Whole Genome Sequencing 30x

Bibliography

Simpson KL, MacLeod EL, Kakajiwala A, et al. Urea Cycle Disorders Overview. GeneReviews®. 2025 Update.

Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019;42(6):1192-1230.

Häberle J, Shchelochkov OA, Wang J, et al. Molecular defects in human carbamoyl phosphate synthetase I: mutational spectrum, diagnostic and protein structure considerations. Hum Mutat. 2011;32(6):579-589.

Hu L, Diez-Fernandez C, Rüfenacht V, et al. Recurrence of carbamoyl phosphate synthetase 1 deficiency in Turkish patients: characterization of a founder mutation. Mol Genet Metab. 2014;113(1-2):127-130.

Musunuru K, Grandinette SA, Wang X, et al. Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. N Engl J Med. 2025;392(22):2235-2243.

What do your genes say about you? Start your journey today.

Get a special 5% discount on your first kit.

Haven't you taken our DNA test yet?

Get your genetic test and discover what your DNA says about you.

pack
Starter DNA test
The best option to get started

Ancestry service, Traits and Wellness

Buy
pack
DNA test Advanced DNA test
Know your DNA in depth

Health, Ancestry service, Traits and Wellness

Buy
pack
Genetic analysisUltra
Whole Genome Sequencing 30x

Health, Ancestrality, Traits and Wellness

includes three months of tellmeGen+

Buy

Important information and limitations

Europe
Austria
Belgium
Czech Republic
Denmark
Finland
Germany
Hungary
Ireland
Italy
Netherlands
Norway
Poland
Portugal
Romania
Spain
Sweden
Switzerland
United Kingdom
Asia
Kazakhstan
Saudi Arabia
UAE
America
Brazil
Canada
Chile
Colombia
Mexico
Panama
Peru
United States
Oceania
Australia
The Best Prices of the Year! Only until November 27 Use our coupon BLACK15
Buy